In August 2018 Neova Technologies Inc. (NTI), a Bioseutica Group company had an inspection by Health Canada and received a compliance rating indicating that the activities inspected met the requirements outlined in the Canadian Food & Drug Act and its associated regulations. NTI has received their Establishment License to manufacture, package, label and test non-sterile Active Pharmaceutical Ingredients (APIs) specifically Trypsin. Neova Technologies Inc. produce pancreatic enzymes such as trypsin, chymotrypsin, phospholipase A2 for food, diagnostics, healthcare and feed industries. Used for infant formulas, tissue, cell biology/cell structure, vaccine production, as a processing aid and as pharmaceutical active ingredient. Bioseutica is a world leader in the pharmaceutical egg lysozyme, egg proteins and pancreatic enzymes market. Bioseutica natural proteins and enzymes are innovative and selected as the first choice for food, feed and pharma sectors.